239 results on '"Maillard, Luc"'
Search Results
2. Prevalence and location of coronary artery disease in anomalous aortic origin of coronary arteries
3. Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial
4. One year results of coronary bifurcation revascularization with the re-POT provisional sequential technique. The CABRIOLET registry
5. Erratum to “One year results of Coronary bifurcation revascularization with the re-POT provisional sequential technique. The CABRIOLET registry” [Int J Cardiol. 2024 Feb 15;397:131632.]
6. Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years.
7. MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF™ NanoCoated Coronary Stent (NCS) Implantation
8. Toward a sequential provisional coronary bifurcation stenting technique. From kissing balloon to re-POT sequence
9. Time Course of Reendothelialization with Polyzene-F Nanocoated Cobra PzF™ Coronary Stent on Rabbit Iliac Arteries
10. Thrombus burden management during primary coronary bifurcation intervention: a new experimental bench model
11. Sequential coronary bifurcation revascularization with the Xposition S™ self-apposing stent: a comparative fractal bench study
12. 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
13. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry
14. TCT-185 Safety and Performance Registry for an All-Comers Subject Population With the Limus-Eluting Orsiro Mission Stent System Within Daily Clinical Practice: 12-Month Results of the BIOFLOW-VIII Registry
15. Polymer-free drug-coated coronary stents in diabetic patients at high bleeding risk: a pre-specified sub-study of the LEADERS FREE trial
16. Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent
17. Safety and Efficacy of Polymer-Free Biolimus A9–Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy
18. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel)
19. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System
20. The POT-PUFF sign: an angiographic mark of stent malapposition during proximal optimisation
21. Preclinical evaluation of a novel polyphosphazene surface modified stent
22. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: The Randomized, Multicenter ITALIC Trial
23. Five-year clinical outcomes using the bioresorbable vascular scaffold: Insights from the FRANCE ABSORB registry
24. Five-Year Clinical Outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System
25. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity
26. Safety and efficacy outcomes of 3rd generation DES in an all‐comer population of patients undergoing PCI: 12‐month and 24‐month results of the e‐Biomatrix French registry
27. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial
28. High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes
29. Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE)
30. Future culprit detection based on angiography-derived FFR
31. TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial
32. Head to head comparison of quantitative flow ratio using 4‐French and 6‐French catheters versus fractional flow reserve
33. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial
34. Relation of Body Mass Index to High On-Treatment Platelet Reactivity and of Failed Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients Undergoing Percutaneous Coronary Intervention
35. Polymer ‐free Biolimus‐A9 coated thin strut stents for patients at high bleeding risk 1‐year results from the LEADERS FREE III study
36. Future culprit detection based on angiography‐derived FFR
37. Association of sex with outcomes in patients undergoing percutaneous coronary intervention: a subgroup analysis of the global leaders randomized clinical trial
38. Validation of the all-comers design:Results of the TARGET-AC substudy
39. Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS in AMI)
40. Quantitative Flow Ratio Analysis by Paramedical Compared With Medical Users.
41. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
42. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
43. Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high‐risk patients: The e‐Cobra study
44. Validation of the all-comers design: Results of the TARGET-AC substudy
45. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention
46. Head to head comparison of quantitative flow ratio using 4‐French and 6‐French catheters versus fractional flow reserve.
47. Polymer‐free Biolimus‐A9 coated thin strut stents for patients at high bleeding risk 1‐year results from the LEADERS FREE III study.
48. Anticoagulant (Fluindione)-Aspirin Combination in Patients with High-Risk Atrial Fibrillation: A Randomized Trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS)
49. Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high-risk patients: The e-Cobra study.
50. Prospective evaluation of drug eluting self‐apposing stent for the treatment of unprotected left main coronary artery disease: 1‐year results of the TRUNC study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.